DB 1310
Alternative Names: DB-1310Latest Information Update: 09 Aug 2026
At a glance
- Originator Duality Biologics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Biliary cancer; HER2 negative breast cancer; HER2 positive breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours; Squamous cell cancer
Most Recent Events
- 31 Dec 2025 Efficacy and adverse event data from a phase I/II trial in Breast cancer released by Duality Biologics
- 09 Dec 2025 Efficacy and adverse event data from a phase I/II trial in Breast cancer presented at the 48th Annual San Antonio Breast Cancer Symposium (SABCS-2025)
- 17 Oct 2025 Synnovation in collaboration with DualityBio plans to initiate a clinical trial (Combination therapy)